Pseudovirus News and Research

RSS
Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Preclinical study finds sex differences in neurological response to SARS-CoV-2 infection

Preclinical study finds sex differences in neurological response to SARS-CoV-2 infection

How did SARS-CoV-2 first evolve in humans?

How did SARS-CoV-2 first evolve in humans?

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Host cell transmembrane protein MARCH8 targets lysine residues to inhibit SARS-CoV-2 and other viruses

Host cell transmembrane protein MARCH8 targets lysine residues to inhibit SARS-CoV-2 and other viruses

Potential new COVID vaccine from Australia

Potential new COVID vaccine from Australia

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Nanobody cocktails neutralize SARS-CoV-2 and variants

Nanobody cocktails neutralize SARS-CoV-2 and variants

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape